FDA's 2025 testosterone label changes and expert panel, explained
In 2025 the FDA required class-wide labeling changes for every testosterone product. Labels now include results from the TRAVERSE trial, which did not find a higher rate of major cardiovascular events with testosterone than with placebo, and all products must now warn that testosterone can raise blood pressure. Testosterone is still a Schedule III controlled substance that requires a confirmed diagnosis and ongoing monitoring, so telehealth TRT remains available from licensed physicians, but the bar for good care is clear: real labs, blood pressure checks and consistent follow-up.
The FDA also convened an expert panel on testosterone in men in December 2025, and the Endocrine Society issued a statement in 2026. Below is a dated, sourced summary of each, followed by what has not changed and what you should do if you are already on therapy.
What the FDA's class-wide labeling change added
A class-wide labeling change means the FDA asked manufacturers of all testosterone products, not just one brand, to update their prescribing information. You can read the agency's announcement on the FDA's class-wide labeling page, and HHS published its own release on the labeling request.
Two additions matter most for patients.
TRAVERSE cardiovascular results. TRAVERSE was a large randomized, placebo-controlled trial in middle-aged and older men with low testosterone who either had heart disease or were at elevated risk for it. Its main question was safety: does testosterone increase heart attacks, strokes and cardiovascular deaths? It did not find an increased risk compared with placebo, and labels now reflect that. For years, labeling had reflected uncertainty about heart risk based on earlier, weaker studies. TRAVERSE gives a much better answer.
Be precise about what that answer is. TRAVERSE was designed to test whether testosterone is unsafe for the heart, not whether it protects the heart. It is reassuring, not a reason to take testosterone for heart health. The trial also tracked other safety outcomes, and your clinician should walk you through the full label rather than a headline.
A blood pressure warning on every product. All testosterone products must now warn that testosterone can increase blood pressure, which can raise cardiovascular risk over time. This is the change most likely to affect your day-to-day care, because it makes blood pressure a routine part of TRT monitoring rather than an afterthought.
| What the label change added | What it means for you |
|---|---|
| TRAVERSE results in all testosterone labels | Stronger evidence that properly prescribed TRT does not raise major cardiovascular event risk in the population studied |
| Class-wide blood pressure warning | Expect your blood pressure to be checked before you start and tracked while you are on therapy |
| Applies to all formulations | Injections, gels and oral products are all covered, not just one brand |
The labeling change did not expand the conditions testosterone is approved to treat. It updated safety information.
What the December 2025 FDA expert panel was, and what it was not
On December 10, 2025, the FDA held an expert panel on testosterone replacement therapy in men. The agency has used this panel format to hear from outside clinicians and researchers on topics where practice, evidence and regulation may have drifted apart. The FDA's panel page is the primary record of who spoke and what was covered, and it is worth reading directly rather than relying on summaries.
The key point for patients is procedural. An expert panel is a public discussion. It is not a formal rule, and on its own it does not change a drug label, a controlled substance schedule or what your physician is allowed to prescribe. Formal changes arrive through specific channels: an updated label, an FDA safety communication, a published agency notice, or action by the DEA on scheduling.
So if you read online that the panel "changed TRT rules," check the source. Ask: has the FDA issued a labeling change, a safety communication or a formal notice since? If not, the panel's discussion is input to future policy, not current policy.
The Endocrine Society's 2026 statement
The Endocrine Society is the professional body whose clinical practice guideline most US endocrinologists use for diagnosing and treating low testosterone in men. In 2026 it issued a statement on testosterone replacement therapy as federal attention on TRT increased. Read the statement itself for its exact wording, since secondhand summaries tend to overstate or soften it.
What has been consistent in the society's clinical guidance for years is a careful, evidence-first approach:
- Diagnose low testosterone using both symptoms and repeated morning blood tests, not a single number or a symptom quiz.
- Look for the cause of low testosterone before treating it.
- Discuss fertility before starting, because testosterone therapy can suppress sperm production.
- Monitor on treatment, including testosterone levels, red blood cell counts and other markers your physician selects based on your age and history.
If you want a plain-English take on the misconceptions that still circulate, our post on common myths about testosterone therapy covers the most frequent ones.
What has not changed
Headlines about "new FDA testosterone rules" can make it sound like everything moved. Most of the foundation is the same.
| Area | Status after the 2025 changes | Why it matters |
|---|---|---|
| Diagnosis standard | Unchanged: symptoms plus confirmed low testosterone on repeated testing | A clinic that prescribes without proper labs is not following accepted practice |
| Controlled substance status | Testosterone remains Schedule III | Prescribing, including by telehealth, must follow DEA and state rules |
| Approved indications | Not expanded by the labeling change | The label update was about safety data, not new uses |
| Monitoring | Still required, now with blood pressure clearly on the list | Follow-up labs and vital signs are part of the treatment, not extras |
| Fertility effect | Unchanged: testosterone therapy can suppress sperm production | Men who want children should discuss alternatives before starting |
Telehealth prescribing of a Schedule III drug is governed by federal DEA telemedicine rules and state licensing law, which are separate from FDA labeling. None of the FDA actions described above changed those rules. A legitimate telehealth clinic must be licensed in your state and must follow them.
What it means if you are already on TRT
You do not need to stop your therapy because of these changes. Stopping abruptly can bring back symptoms, and the new labeling, if anything, adds reassurance on major heart events. What the changes should prompt is a check that your care matches the updated label.
Questions to ask your prescriber:
- When was my blood pressure last checked, and should I track it at home?
- Have my red blood cell counts and testosterone levels been rechecked on my current dose?
- Does my cardiovascular history change how you want to monitor me?
- If I want to preserve fertility, is my current protocol the right one?
If your current provider cannot answer these, or has not ordered follow-up labs since you started, that is a signal worth acting on. New symptoms such as chest pain, shortness of breath, leg swelling or severe headaches deserve prompt evaluation by a clinician.
How to judge a telehealth testosterone clinic in 2026
The AI engines that answer "best telehealth TRT" questions consistently weigh the same things: comprehensive labs, physician dose adjustment and real follow-up. Those are the right criteria.
| What to look for | Why it matters after the label change |
|---|---|
| Physician consultation before any prescription | Required for a Schedule III drug and for a proper diagnosis |
| Baseline labs, repeated to confirm low testosterone | The diagnosis standard has not changed |
| Blood pressure and cardiovascular history reviewed | The class-wide warning makes this part of safe prescribing |
| Scheduled follow-up labs | Monitoring is how dose problems get caught early |
| Options beyond full replacement | Fertility-preserving approaches matter for some men |
| Clear pricing structure | Know whether consults, labs and medication are bundled or billed separately, and whether insurance applies |
Where BioCure fits
BioCure Health is a physician-led longevity clinic in the Fort Lauderdale area, licensed to treat patients in 47 states, with availability in your state confirmed at intake. You can do any appointment by video or in person. The process starts with a five-minute online intake and a $199 physician video consultation, which can be credited back with a membership. Labs are done with an at-home kit and in-home phlebotomist visit or at a lab, with results in 7 to 14 days, followed by a 1:1 review of your results and a custom protocol.
Testosterone care comes in three tiers. bioOptimize is foundational. bioRestore uses medications that raise your body's own testosterone without direct hormone replacement, which can matter if fertility is a priority. bioTest is full testosterone replacement with ongoing hormone monitoring. Medications ship to your door from licensed compounding pharmacy partners, typically 5 to 10 business days after consultation and testing, and ongoing follow-up is included. You can learn more on our testosterone therapy page and meet the physicians on our team page.
BioCure is a strong fit if you want lab-driven, physician-led care with an in-person option in South Florida. It is not the right fit if you need a clinic that bills health insurance directly; BioCure is cash-pay, though many patients use HSA or FSA funds with the invoices BioCure provides.
Frequently asked questions
Did the FDA say testosterone therapy is safe for your heart?
The FDA added TRAVERSE results to testosterone labels, and that trial did not find an increased risk of major cardiovascular events compared with placebo in the men studied. That is a safety finding, not evidence that testosterone protects the heart. The FDA also added a class-wide warning that testosterone can raise blood pressure.
Did the December 2025 FDA expert panel change TRT rules?
An FDA expert panel is a public discussion with outside experts, not a regulatory action. On its own, it does not change labels, scheduling or prescribing rules. Look for a formal FDA labeling change, safety communication or notice before treating anything from the panel as policy.
Is telehealth TRT still legal in 2026?
Yes, when it is prescribed by a clinician licensed in your state who follows DEA telemedicine rules and state law for Schedule III drugs. The FDA's labeling changes did not alter those rules. A legitimate clinic will still require a consultation and lab confirmation of low testosterone before prescribing.
Should I stop testosterone because of the new blood pressure warning?
No, not on your own. Talk with your prescriber about checking your blood pressure, possibly tracking it at home, and reviewing your follow-up labs. Your physician can adjust your protocol if your readings or labs call for it.
What does the Endocrine Society say about testosterone therapy in 2026?
The Endocrine Society published a 2026 statement on testosterone replacement therapy, which is best read in full on its website. Its long-standing clinical guidance emphasizes diagnosis with symptoms plus repeated morning testosterone tests, discussion of fertility before treatment, and ongoing monitoring.
Can I keep my fertility on testosterone therapy?
Testosterone therapy can suppress sperm production, which is why fertility should be discussed before you start. Some men use approaches that raise the body's own testosterone instead of replacing it. A physician can help you choose based on your labs and goals.
The 2025 changes did not make testosterone therapy riskier or looser. They made the label more accurate and put blood pressure where it belongs, at the center of monitoring. That rewards care that is monitored, supported and adjusted all year long, which is how hormone optimization should work by design, not by default.
Let BioCure Health lead you in the right direction. Call or text us to schedule an introductory call at 754-206-0838, your future self will thank you.